Sanjay S. Shukla
2021
In 2021, Sanjay S. Shukla earned a total compensation of $1.9M as President and CEO at aTYR PHARMA, a 75% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $293,377 |
---|---|
Option Awards | $1,076,297 |
Salary | $510,221 |
Other | $12,813 |
Total | $1,892,708 |
Shukla received $1.1M in option awards, accounting for 57% of the total pay in 2021.
Shukla also received $293.4K in non-equity incentive plan, $510.2K in salary and $12.8K in other compensation.
Rankings
In 2021, Sanjay S. Shukla's compensation ranked 6,250th out of 12,415 executives tracked by ExecPay. In other words, Shukla earned more than 49.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,250 out of 12,415 | 50th |
Division Manufacturing | 2,653 out of 5,508 | 52nd |
Major group Chemicals And Allied Products | 1,162 out of 2,378 | 51st |
Industry group Drugs | 1,034 out of 2,099 | 51st |
Industry Biological Products, Except Diagnostic Substances | 250 out of 449 | 44th |
Source: SEC filing on March 22, 2022.
Shukla's colleagues
We found two more compensation records of executives who worked with Sanjay S. Shukla at aTYR PHARMA in 2021.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019